ArticleBMC oral health2025
Prognostic factors and survival outcomes in patients with salivary duct carcinoma: a retrospective cohort study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.Oncology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalivary duct carcinoma (SDC) is a highly aggressive salivary gland malignancy with poor prognosis. The aim was to investigate the prognostic factors and survival outcomes in a cohort of SDC patients. MATERIALS AND
methodsThis study retrospectively analyzed the clinicopathological data of 61 SDC patients treated at the First Medical Center of the PLA General Hospital between January 2010 and December 2020. Univariate and multivariate Cox proportional hazards models were used to identify prognostic factors for overall survival (OS). Fine-Gray subdistribution hazard model was used to analyze prognostic factors for cancer-specific mortality.
resultsOf the 61 patients, the parotid gland was the most common primary site (70.5%). Lymph node and distant metastases were present in 35 (57.4%) and 23 (37.7%) patients, respectively. The 5-year and 3-year OS rates were 35.2% and59.7%. Multivariate analysis identified platelet count (HR 0.99, 95%CI 0.98-1.00, P = 0.011) and distant metastasis (HR 2.79, 95%CI 1.38-5.64, P = 0.004) as independent prognostic factors for OS. Lymph node metastasis (SHR = 2.18, 95%CI 1.05-4.52, P = 0.036), distant metastasis (SHR = 3.07, 95%CI 1.47-6.42, P = 0.003), and platelet count (SHR = 0.99, 95%CI 0.99-1.00, P = 0.041) were independent prognostic factors for cancer-specific mortality.
conclusionsDistant metastasis and thrombocytopenia are important predictors of poor overall survival in SDC patients. These findings underscore the potential significance of incorporating hematological parameters and metastatic status into clinical decision-making to optimize risk stratification and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.